Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy

Kowalska, Irina; Borawski, Jacek; Nikołajuk, Agnieszka; Budlewski, Tadeusz; Otziomek, Elżbieta; Górska, Maria; Strączkowski, Marek

doi:10.1007/s12020-011-9446-5

Cited by 41 publications

(24 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One explanation would be levothyroxine replacement causing a decrease in chronic inflammation, which plays an important role in HT. Previous studies showed decreased TNF-α, interleukin (IL)-1β, IL-6, and monocyte chemoattractant protein-1 levels in euthyroid group (24), decreased intercellular adhesion molecule-1 levels in subclinical hypothyroid group (25), and decreased C-reactive protein levels in another subclinical hypothyroid group after levothyroxine replacement (26). In addition, levothyroxine replacement has also been shown to decrease lymphocyte infiltration in rats and cats with HT (27,28).…”

Section: Discussionmentioning

confidence: 99%

The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto’s thyroiditis

Ateş

Altay

Yılmaz

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Although several studies reported increased oxidative stress in Hashimoto's thyroiditis (HT), the effect of levothyroxine treatment on oxidative status is not studied extensively. Therefore, we conducted this study to investigate the effects of levothyroxine replacement on oxidative stress in HT. Design and methods: Thirty-six patients recently diagnosed with HT-related hypothyroidism and 36 healthy controls were included in the study. Levothyroxine replacement was started to patients with hypothyroidism, and had been followed-up for 6 months. Results: Mean basal serum total antioxidant status (TAS), total thiol, arylesterase, and paraoxonase 1 (PON1) levels were significantly lower, and serum total oxidant status (TOS) and oxidative stress index (OSI) were significantly higher in the patients with hypothyroid than the controls. In the hypothyroid group serum TAS, total thiol, arylesterase, and PON1 levels increased and serum TOS and OSI levels decreased significantly after levothyroxine treatment. Pretreatment serum TAS, total thiol, PON1, and arylesterase levels were positively correlated with free levothyroxine (fT 4 ) and negatively correlated with thyroid-stimulating hormone (TSH), antithyroid peroxidase (anti-TPO), and antithyroglobulin (anti-TG) levels. Also, pretreatment serum TOS and OSI levels were negatively correlated with fT 4 levels and positively correlated with TSH, anti-TPO, and anti-TG. We have also found that the fT 4 and anti-TPO levels are independent predictors of the oxidative stress parameters in stepwise multivariable linear regression analysis. Conclusion: This study suggests that levothyroxine replacement decreases oxidant status and increases antioxidant status following the 6 months of levothyroxine replacement in hypothyroidism that develops in accordance with the HT.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto’s thyroiditis

Ateş

Altay

Yılmaz

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Some studies demonstrated that subclinical hypothyroidis leads to insulin resistance [31,32], but other studies did not observe this effect [33,34]. The reason for the differences in the obtained results may be due to different durations and degrees of subclinical hypothyroidism.…”

Section: Prace Oryginalnementioning

confidence: 94%

Powiązania między zespołem metabolicznym, subkliniczną niedoczynnością i autoimmunologicznym zapaleniem tarczycy u kobiet po menopauzie oraz rola interleukiny-6

Siemińśka

Wojciechowska

Walczak

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: The prevalence of metabolic syndrome increases after menopause; however, the role of concomitant subclinical hypothyroidism has not been completely elucidated. The aim of the study was to identify associations between thyrotropin, immune status, inflammation, and metabolic syndrome in postmenopausal women. The specific goals were: to assess thyrotropin (TSH) and interleukin-6 (IL-6) concentrations in the serum of subclinical hypothyroid postmenopausal women with and without metabolic syndrome and compare them with euthyroid controls; to test whether immune status is related to metabolic syndrome in postmenopausal women and determine the role of IL-6; to examine the relationships between TSH and different features of metabolic syndrome: insulin resistance, waist circumferences, waist-to-hip ratio (WHR), BMI, metabolic parameters (triglycerides, total cholesterol and high-density lipoprotein cholesterol), and inflammatory cytokines (IL-6). Material and methods: Three hundred and seventy-two postmenopausal women were included in the study: 114 women had subclinical hypothyroidism (10.0 uIU/mL > TSH ≥ 4.5 uIU/mL, normal fT4), and 258 women were in euthyreosis (TSH 0.35-4.5 uIU/mL, normal fT4); both groups were matched by age. Anthropometric measurements were conducted (BMI, waist circumference, WHR) and blood pressure was measured. In all subjects the following were assessed in serum: lipid profile, glucose, insulin, TSH, fT4, thyroid antibodies (T-Abs) -TPO-Abs, TG-Abs, and IL-6 concentrations. Results: The prevalence of metabolic syndrome was 49.12% in subclinical hypothyroid women and 46.89% in euthyroid women. However, the proportion of subjects with one or two abnormalities was significantly higher in the subclinical hypothyroid group (45.61%) than in the euthyroid group (32.17%). When we compared subclinical hypothyroid women with and without metabolic syndrome, subjects with metabolic syndrome had higher BMI, abdominal circumferences, WHR, and HOMA-I. They presented higher systolic and diastolic blood pressure. Serum concentrations of cholesterol, triglycerides, fasting glucose, IL-6, TSH, T-Abs were also higher and serum cHDL was lower. There were no significant differences in fT4 concentrations. A similar comparison was made for euthyroid women with and without metabolic syndrome. Higher BMI, waist circumference, WHR, HOMA-I, and systolic blood pressure were observed in subjects with metabolic syndrome. Serum concentrations of TSH, triglycerides, glucose, and IL-6 were also higher, but the concentration of cHDL was significantly lower. There were no significant differences in fT4, T-Abs, cholesterol levels, and diastolic pressure. When we compared euthyroid women T-Abs (+) and T-Abs (-), the prevalence of metabolic syndrome was similar (48.68% vs. 46.15%). There were no differences in BMI, waist circumference, WHR, lipid profile, glucose, and HOMA-I, fT4. However, thyroid autoimmunity was associated with elevated TSH and IL-6 levels. When we analysed subclinical hypothyroid women with ...

show abstract

“…47, [67][68][69][70][71] Overall, it appears that the beneficial effect-if any-of levothyroxine treatment on lipid profile in SCH mainly concerns TC and LDL-C levels. TG concentrations are not significantly affected.…”

Section: Effect Of Levothyroxine Treatmentmentioning

confidence: 99%

“…As far as HDL-C is concerned, most studies demonstrate no significant effect of levothyroxine substitution on HDL-C concentrations in SCH. 16,18,20,24,47,[60][61][62][63][65][66][67]69,70 Nevertheless, there is limited evidence suggesting either a lowering 15,17,59,72 or an increasing effect.…”

Section: Effect Of Levothyroxine Treatmentmentioning

confidence: 99%

Subclinical hypothyroidism and vascular risk: Αn update

Lioudaki¹,

Mavroeidi²,

Mikhailidis³

et al. 2013

View full text Add to dashboard Cite

subclinical hypothyroidism (scH), defined as elevated serum thyroid-stimulating hormone (tsH) in the presence of normal circulating free thyroxine (Ft4) and triiodothyronine (t3), is a relatively common condition. replacement treatment with levothyroxine is justified only for individuals with tsH levels >10 mIU/l. serum lipid levels are influenced by thyroid status and there is evidence pointing to a link between scH and an unfavorable lipid profile. Despite some conflicting data, most studies suggest that levothyroxine treatment may exert a beneficial effect on the lipid profile in scH regarding mainly total cholesterol and low-density lipoproteincholesterol. Moreover, it appears that treatment may also improve some other markers associated with cardiovascular (cV) disease such as carotid intima media thickness ( 17-03-201317-03- , Accepted 20-10-2013 Review (FT4) and triiodothyronine (T3) levels within the reference range.1 This is a relatively common condition with a prevalence ranging from 4 to 15% in the general population and up to 20% among females aged >60 years. [2][3][4][5]

show abstract

Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy

Cited by 41 publications

References 46 publications

The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto’s thyroiditis

The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto’s thyroiditis

Powiązania między zespołem metabolicznym, subkliniczną niedoczynnością i autoimmunologicznym zapaleniem tarczycy u kobiet po menopauzie oraz rola interleukiny-6

Subclinical hypothyroidism and vascular risk: Αn update

Contact Info

Product

Resources

About